Actively Recruiting
Phase I Study of SIBP-A10 Injection to Assess Safety and Effectiveness in Adults with Advanced Malignant Tumors
Led by Shanghai Institute Of Biological Products · Updated on 2026-01-08
160
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, preliminary anti-tumor effects, immunogenicity, and potential biomarkers of SIBP-A10 injection in people with advanced metastatic tumors. This open-label study includes dose escalation, dose expansion, and indication expansion phases to find the maximum tolerated dose MTD and the recommended dose for phase II RP2D. The study involves adults aged 18 to 75 years with measurable tumors and good physical status. Participants will receive SIBP-A10 via intravenous infusion at doses ranging from 0.5 to 15 mgkg, given once every 21 days. The first phase uses a dose escalation design to identify safe dose levels, followed by dose expansion with selected doses to further evaluate safety and effects. The final phase uses the recommended dose to explore treatment in different tumor types, enrolling at least 40 participants per indication group. During the study, participants will have assessments for adverse events, dose-limiting toxicities, pharmacokinetics drug levels over time, tumor responses, and survival. Safety monitoring includes evaluation of heart rhythm effects and immune reactions. Tumor tissue samples and biopsies may be collected. The study spans several months, with follow-up to 36 months after the first injection to observe overall survival and other outcomes.
CONDITIONS
Brief Title
A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.
Research Team
D
Dan dan Chen, Master
B
Bao Yuan Shang, Master
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here